BPC-157 has become one of the most talked-about elements in health and fitness circles, yet the science behind it remains surprisingly thin. In a recent episode of the Huberman Lab podcast, Andrew Huberman spoke with Dr. Abu Bakri, an internal medicine physician with deep knowledge of peptide science, to unpack what is actually known, and what remains uncertain.
BPC-157 is a 15–amino acid fragment derived from a much larger 40,000 dalton protein called BPC, found in gastric tissue. It does not naturally exist in this isolated form in the human body.
It was first identified by a Croatian research group in the early 1990s, inspired in part by Ivan Pavlov’s earlier observations that gastric juices seemed to have protective effects on the stomach lining. Researchers hypothesised that something within those juices was responsible for this protective action, and BPC-157 was eventually isolated as a key active fragment.
A wide range of animal studies followed, including models involving severed tendons, burn wounds, and neurological injury. Across these experiments, the Croatian group reported that BPC-157 appeared to accelerate healing across multiple tissue types.
In one frequently cited Achilles tendon study, faster recovery rates were observed after administration of the element. In other experiments, it appeared to protect the gastric lining even when corticosteroids were present, d**gs that are typically known to slow wound healing.
However, Dr. Bakri pointed out that much of the attention around BPC-157’s musculoskeletal effects may overlook its original purpose.
“The original idea of BPC was to use it as a gastric treatment, not to use it as a musculoskeletal tool,” he said, emphasising that its development was initially centred on gastrointestinal applications rather than injury recovery.
One of the key scientific challenges with BPC-157 is that it has no identified receptor. Unlike dr**s such as GLP-1 agonists, which bind to well-characterised receptors and produce predictable downstream effects, BPC-157’s mechanism of action remains unclear.
It may influence existing proteins, alter gene transcription, or act through biological pathways that have not yet been mapped. This absence of a known receptor makes the compound difficult to study, standardise, or regulate in a conventional pharmacological framework.
Despite its growing popularity, human clinical data on BPC-157 is limited. Only one Phase 1 and one small Phase 2 trial have been conducted, both in Croatia and using rectal enema administration at doses significantly higher than those typically used in informal settings.
The Phase 1 trial reported no adverse effects, while the Phase 2 study suggested a potential benefit in ulcerative colitis. However, only abstracts from these studies are publicly available, with full datasets remaining inaccessible.
Another frequently discussed concern is BPC-157’s apparent influence on angiogenesis through VEGF signalling, which promotes the formation of new blood vessels. While this may support tissue repair and regeneration, it has raised theoretical concerns about whether it could also accelerate the growth of undetected tumours.
Dr. Bakri acknowledged that no direct evidence of carcinogenic effects has been observed in animal studies, but also cautioned that most available data originates from a single research group.
Ultimately, BPC-157 occupies a complicated space in biomedical research: it is supported by decades of intriguing animal data and widespread anecdotal use, but lacks robust human trials, a clearly defined mechanism of action, and comprehensive safety profiling.
As Dr. Bakri summarised, “BPC is very promising. It has all this cool literature in animals and we just don’t know when it comes to the one.” He was referring to the absence of meaningful large-scale human evidence.
For those considering its use, his advice remained cautious: it should only be approached under medical supervision, ideally with properly sourced pharma-grade material, while keeping in mind that the unknowns around its long-term effects are still significant.
